CA3196210A1 - Anticancer compounds selective for er-positive cancers - Google Patents

Anticancer compounds selective for er-positive cancers

Info

Publication number
CA3196210A1
CA3196210A1 CA3196210A CA3196210A CA3196210A1 CA 3196210 A1 CA3196210 A1 CA 3196210A1 CA 3196210 A CA3196210 A CA 3196210A CA 3196210 A CA3196210 A CA 3196210A CA 3196210 A1 CA3196210 A1 CA 3196210A1
Authority
CA
Canada
Prior art keywords
compound
erso
dfp
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196210A
Other languages
English (en)
French (fr)
Inventor
Paul J. Hergenrother
Matthew Boudreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CA3196210A1 publication Critical patent/CA3196210A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3196210A 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers Pending CA3196210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104933P 2020-10-23 2020-10-23
US63/104,933 2020-10-23
PCT/US2021/056003 WO2022087234A1 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers

Publications (1)

Publication Number Publication Date
CA3196210A1 true CA3196210A1 (en) 2022-04-28

Family

ID=81290080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196210A Pending CA3196210A1 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers

Country Status (9)

Country Link
US (1) US12655104B2 (enExample)
EP (1) EP4232038A4 (enExample)
JP (1) JP2023546584A (enExample)
CN (1) CN116723841A (enExample)
AU (2) AU2021366688B2 (enExample)
CA (1) CA3196210A1 (enExample)
IL (1) IL302154A (enExample)
MX (1) MX2023004480A (enExample)
WO (1) WO2022087234A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981469A (zh) * 2023-02-23 2025-11-18 晨晖生物科技(香港)有限公司 含硼化合物及其治疗用途
WO2026039467A1 (en) * 2024-08-12 2026-02-19 The Board Of Trustees Of The University Of Illinois Hydroxyphenyl-indoline-2-one cancer therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2855406A (en) 1955-05-07 1958-10-07 Dann Otto Preparation of benzopyrans and benzofurans
US3773759A (en) 1972-08-21 1973-11-20 Searle & Co 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CA2684552A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
CN108440378B (zh) 2018-03-27 2021-03-12 宁波大学 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法
EP3817741A4 (en) * 2018-07-03 2022-07-06 The Board of Trustees of the University of Illinois ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE

Also Published As

Publication number Publication date
AU2021366688A9 (en) 2024-06-20
MX2023004480A (es) 2023-05-04
US12655104B2 (en) 2026-06-16
EP4232038A4 (en) 2024-04-10
IL302154A (en) 2023-06-01
AU2021366688A1 (en) 2023-05-25
JP2023546584A (ja) 2023-11-06
EP4232038A1 (en) 2023-08-30
AU2026204244A1 (en) 2026-06-18
WO2022087234A1 (en) 2022-04-28
US20230391721A1 (en) 2023-12-07
CN116723841A (zh) 2023-09-08
AU2021366688B2 (en) 2026-03-05

Similar Documents

Publication Publication Date Title
JP7662639B2 (ja) エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用
KR20220012274A (ko) 플루오린 함유 화합물 및 이의 항암 의학적 용도
TWI837402B (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
JP2022513959A5 (enExample)
CA2879798C (en) Procaspase enzyme-activating substituted 2-(4-benzylpiperazin-1-yl)-n'-(2-hydroxybenzylidene)acetohydrazide derivatives and compostions thereof
US20130096133A1 (en) Procaspase-activating compounds and compositions
JP2024512544A (ja) テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
US20260103470A1 (en) Androgen receptor regulation by small molecule enantiomers
CA3103958A1 (en) Activators of the unfolded protein response
AU2021366688B2 (en) Anticancer compounds selective for er-positive cancers
US20220089602A1 (en) Compounds that induce ferroptic cell death
US12312354B2 (en) Selective BTK irreversible inhibitors
WO2021222738A1 (en) Compounds for estrogen receptor positive cancers
CN116438177A (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
US11274106B2 (en) Topoisomerase inhibitors with antibacterial and anticancer activity
WO2026039467A1 (en) Hydroxyphenyl-indoline-2-one cancer therapeutics
US20250376477A1 (en) Analgesic delta opioid receptor bitopic ligands
US12552806B2 (en) Androgen receptor regulation by small molecule enantiomers
WO2025029660A9 (en) Compounds with selectivity for certain cancers
CN107266468A (zh) 含吡唑啉结构的噻喃并嘧啶类化合物的制备及应用
KR101048748B1 (ko) 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
WO2020210125A1 (en) Deuterated antimicrobial compounds

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251017

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251017

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251017

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251217

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122